Clinical Trials Directory

Trials / Completed

CompletedNCT00174772

Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC)

A Two Arm Phase II Study Comparing Docetaxel/Cisplatin Induction Therapy Followed By Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Followed By Consolidation Docetaxel/Cisplatin in Patients With Locally Advanced Unresectable NSCLC (Stage IIIA-Multiple cN2 or IIIB)

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
72 (actual)
Sponsor
Sanofi · Industry
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

Primary Objective: * To evaluate the toxicity/safety profile of docetaxel/cisplatin induction therapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by consolidation docetaxel/cisplatin in patients with locally advanced unresectable NSCLC (stage IIIA- multiple cN2 or IIIB). Secondary Objective: * To estimate efficacy parameters in overall response rate, progression free survival and 1 year survival for each of the two above mentioned arms.

Conditions

Interventions

TypeNameDescription
DRUGdocetaxel and cisplatin followed by concurrent chemoradiotherapy with docetaxel and cisplatin + radiotherapydocetaxel (75mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles, followed by concurrent chemoradiotherapy with docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy
DRUGdocetaxel and cisplatin + radiotherapy followed by docetaxel and cisplatindocetaxel (20mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy followed by docetaxel and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles.

Timeline

Start date
2004-03-01
Primary completion
2009-02-01
Completion
2009-02-01
First posted
2005-09-15
Last updated
2010-02-17

Locations

8 sites across 8 countries: Belgium, Finland, France, Italy, Netherlands, Spain, Turkey (Türkiye), United Kingdom

Source: ClinicalTrials.gov record NCT00174772. Inclusion in this directory is not an endorsement.